Business
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in a humanized ...
About this update from Nanoviricides, Inc.
[{"type":"text","content":"SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in a humanized animal model. The Company announces that NV-387 can now be made available for emergency use application in Measles patients to respond to the spreading Measles outbreaks.","length":428,"tagName":"p"},{"type":"text","content":"Having a drug to treat patients has become of paramount importance, in view of the fact that the USA is about to return to an endemic playground for the Measles virus, with over 1,600 cases as of October 17, breaking a thirty-year-plus-long record this year1.","length":259,"tagName":"p"},{"type":"text","content":""We have already developed an effective drug to respond to the Measles virus outbreaks spreading all across the country," said Anil R. Diwan, PhD, President.","length":167,"tagName":"p"},{"type":"text","content":""NV-387 can be used right away for emergency use in Measles cases," said Krishna Menon, VMD, MRCS, PhD, Consulting Scientist (Non-Clinical), adding, "With my extensive experience with non-clinical development of several marketed drugs, I can definitely say that NV-387 has excellent activity and safety in treating Measles virus infection."","length":360,"tagName":"p"},{"type":"text","content":"Dr. Menon designed and conducted the humanized animal model studies for testing drugs against Measles virus infection. As such, he has hands-on experience with the effects of the drug NV-387. The data has provided compelling evidence that NV-387 is indeed highly effective in protecting the infected from the systemic effects of Measles infection.","length":347,"tagName":"p"},{"type":"text","content":""The drug is manufactured under GMP in the USA," added Jayant Tatake, PhD, Vice President of the Company.","length":115,"tagName":"p"},{"type":"text","content":"NV-387 has already completed Phase I clinical trial in healthy subjects with no reported adverse events.","length":104,"tagName":"p"},{"type":"text","content":"The Company has previously reported that in a humanized animal model of lethal Measles infection, NV-387 treatment increased survival of animals to 17 days on average compared to only 7.4 days in un...